Transcranial alternating current stimulation (tACS) in the treatment of Alzheimer's disease and improvement of cognitive function: clinical randomized controlled study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068381

Enrollment

Unknown

Registered

2023-02-16

Start date

2023-02-17

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

tACS (Transcranial alternating current stimulation) group:Transcranial alternating current stimulation

Sham tACS group:Sham tACS

Control group:No intervention

Eligibility

Sex/Gender

All

Age

55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of the International Classification of Diseases (ICD-10) for Alzheimer's disease; 2. Aged 55-80 years; 3. Right-handed; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with severe physical, infectious and immune system diseases; 2. Patients with severe neurological disease, mental retardation or organic brain disease; 3. Patients with a history of seizures; 4. Patients treated with electroconvulsive therapy within the last 3 months; 5. Patients assessed to be unsuitable for tACS treatment and unable to complete the relevant index collection.

Design outcomes

Primary

Measure	Time frame
HAMD (Hamilton Depression Rating Scale) score;HAMA (Hamilton Rating Scale Anxiety) score;PSQI (Pittsburgh Sleep Quality Index) score;TMS-MEP (Transcranial Magnetic Stimulation Motor Evoked Potentials);TMS-EEG(Transcranial Magnetic Stimulation Electroencephalogram);NIR functional imaging;rs-EEG (resting-state Electroencephalogram);ERP (Event Related Potentials) T;TACS-EEG(tACS (Transcranial alternating current stimulation Electroencephalogram);ADL(Activity of Daily Living);MMSE(mini-mentalstateexamination);ADAS-cog(The Alzheimer’s Disease Assessment Scale–Cognitive Subscale);NPI(neuropsychiatric inventory);SCD-Q(The Subjective Cognitive Decline Questionnaire);	—

Measure

Time frame

HAMD (Hamilton Depression Rating Scale) score;HAMA (Hamilton Rating Scale Anxiety) score;PSQI (Pittsburgh Sleep Quality Index) score;TMS-MEP (Transcranial Magnetic Stimulation Motor Evoked Potentials);TMS-EEG(Transcranial Magnetic Stimulation Electroencephalogram);NIR functional imaging;rs-EEG (resting-state Electroencephalogram);ERP (Event Related Potentials) T;TACS-EEG(tACS (Transcranial alternating current stimulation Electroencephalogram);ADL(Activity of Daily Living);MMSE(mini-mentalstateexamination);ADAS-cog(The Alzheimer’s Disease Assessment Scale–Cognitive Subscale);NPI(neuropsychiatric inventory);SCD-Q(The Subjective Cognitive Decline Questionnaire);

—

Countries

China

Contacts

Public ContactLi xingxing

Ningbo Kangning Hospital

290534201@qq.com13857476641

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026